EA201290799A1 - Лечение желудочно-кишечных расстройств - Google Patents

Лечение желудочно-кишечных расстройств

Info

Publication number
EA201290799A1
EA201290799A1 EA201290799A EA201290799A EA201290799A1 EA 201290799 A1 EA201290799 A1 EA 201290799A1 EA 201290799 A EA201290799 A EA 201290799A EA 201290799 A EA201290799 A EA 201290799A EA 201290799 A1 EA201290799 A1 EA 201290799A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
disease
conditions
peptides
gastrointestinal disorders
Prior art date
Application number
EA201290799A
Other languages
English (en)
Inventor
Ангелика Фретцен
Хун Чжао
Марко Кесслер
Original Assignee
Айронвуд Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875305&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290799(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Айронвуд Фармасьютикалз, Инк. filed Critical Айронвуд Фармасьютикалз, Инк.
Publication of EA201290799A1 publication Critical patent/EA201290799A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

Изобретение относится к пептидам, композициям и соответствующим способам лечения желудочно-кишечных расстройств и состояний, включающих, но не ограничивающихся этим, синдром раздраженного кишечника (СРК), расстройства желудочно-кишечной перистальтики, функциональные желудочно-кишечные расстройства, гастроэзофагеальную рефлюксную болезнь (ГЭРБ), дуоденогастральный рефлюкс, болезнь Крона, язвенный колит, воспалительное заболевание кишечника, функциональную изжогу, диспепсию, висцеральную боль, парез желудка, хроническую кишечную псевдонепроходимость (или толстокишечную псевдонепроходимость), расстройства и состояния, связанные с запором, и другие состояния и расстройства, описанные здесь, используя пептиды и другие агенты, которые активируют рецептор гуанилатциклазы С (GC-C).
EA201290799A 2010-02-17 2011-02-17 Лечение желудочно-кишечных расстройств EA201290799A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30546510P 2010-02-17 2010-02-17
PCT/US2011/025274 WO2011103311A2 (en) 2010-02-17 2011-02-17 Treatments for gastrointestinal disorders

Publications (1)

Publication Number Publication Date
EA201290799A1 true EA201290799A1 (ru) 2013-03-29

Family

ID=43875305

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290799A EA201290799A1 (ru) 2010-02-17 2011-02-17 Лечение желудочно-кишечных расстройств

Country Status (13)

Country Link
US (6) US8933030B2 (ru)
EP (1) EP2536742B1 (ru)
CN (1) CN102869677B (ru)
AU (3) AU2011218009B2 (ru)
CA (1) CA2790213A1 (ru)
DK (1) DK2536742T3 (ru)
EA (1) EA201290799A1 (ru)
ES (1) ES2638589T3 (ru)
MX (1) MX340234B (ru)
PL (1) PL2536742T3 (ru)
TR (1) TR201711271T4 (ru)
UA (1) UA108636C2 (ru)
WO (1) WO2011103311A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702678A (zh) * 2010-09-11 2014-04-02 硬木药品公司 便秘型肠易激综合征的治疗
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
CN104231051B (zh) * 2013-06-06 2020-06-26 深圳翰宇药业股份有限公司 一种利那洛肽的制备方法
NZ717739A (en) 2013-08-09 2023-12-22 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2015166468A1 (en) * 2014-05-02 2015-11-05 Sinoveda Canada, Inc. Formulas comprising highly soluble elements and vitamin d for the prevention and treatment of bowel conditions during calcium supplementation
EA201792401A1 (ru) * 2015-05-01 2018-05-31 Айронвуд Фармасьютикалз, Инк. Композиции для очищения толстого кишечника и лечения желудочно-кишечных расстройств
MA47112A (fr) 2016-12-21 2019-10-30 Ironwood Pharmaceuticals Inc Procédés de traitement du syndrome du côlon irritable avec des formulations à libération modifiée ou retardée de linaclotide
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
CN106831950A (zh) * 2017-03-18 2017-06-13 南京工业大学 一种制备利那洛肽的方法
IT201700054380A1 (it) * 2017-05-19 2018-11-19 Aboca Spa Societa Agricola Composizioni contenenti sistemi di rilascio di anidride carbonica ottenuti da succhi vegetali
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
CA2028848A1 (en) 1989-04-11 1990-10-12 Tapan Audhya Lyophilized peptide formulations
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5654278A (en) 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
DE69722620T2 (de) 1996-07-03 2004-04-29 Alza Corp., Palo Alto Nicht-waessrige protische peptidzubereitungen
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
EP1098636A1 (en) 1998-07-23 2001-05-16 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
CN1161107C (zh) 1998-11-27 2004-08-11 高田宽治 用于胃肠道药物传递的口服制剂
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
KR20080015888A (ko) 2000-06-28 2008-02-20 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002026248A1 (en) 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
DE60127175T2 (de) 2000-12-21 2007-11-08 Nektar Therapeutics, San Carlos Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
WO2002062369A2 (en) 2001-02-02 2002-08-15 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
GB0104371D0 (en) 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US7041786B2 (en) 2001-03-29 2006-05-09 Callisto Pharmaceuticals Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
WO2003014304A2 (en) 2001-08-09 2003-02-20 Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International Protonic formulation
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
AU2002351755A1 (en) 2001-12-21 2003-07-15 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
CN1726012A (zh) 2002-12-11 2006-01-25 辉瑞产品公司 活性物质在高脂肪环境中的控制释放
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BR122018074353B8 (pt) 2003-01-28 2021-07-27 Ironwood Pharmaceuticals Inc composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos
DE602004012745T2 (de) 2003-05-14 2009-04-09 Indus Biotech Pvt. Ltd. Synergistische zusammensetzung zur behandlung von diabetes mellitus
EA009676B1 (ru) 2003-06-10 2008-02-28 Эл Джи Лайф Сайенсиз Лтд. Водный препарат эритропоэтина человека
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
PT1644021E (pt) 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE102004011663B4 (de) 2004-03-10 2006-04-27 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
WO2006071102A1 (en) 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
CA2619650A1 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US7476405B2 (en) 2006-02-23 2009-01-13 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP1996218A4 (en) 2006-02-24 2012-07-11 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
AU2007272272B2 (en) 2006-07-10 2012-04-12 Pba3 Biomed Gmbh Antimicrobial peptides
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
RU2493868C2 (ru) 2006-08-31 2013-09-27 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
JP2010513462A (ja) 2006-12-20 2010-04-30 バイエル・ヘルスケア・エルエルシー 第ＶＩＩおよび第ＶＩＩａ因子組成物
EP2650303A1 (en) 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
CN101772513B (zh) * 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
KR20210145307A (ko) 2008-08-15 2021-12-01 아이언우드 파마슈티컬스, 인코포레이티드 경구 투여를 위한 리나클로타이드-함유 제형
WO2010027404A2 (en) 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulation of therapeutic polypeptides suitable for oral administration
WO2010027405A2 (en) 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration
EP2373296B1 (en) 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
MX2012001691A (es) 2009-08-12 2012-02-29 Forest Lab Holdings Ltd Composiciones de linaclotida que se desintegran oralmente.
DK2521561T3 (en) 2009-11-03 2017-09-11 Ironwood Pharmaceuticals Inc LINACLOTID FOR TREATMENT OF CHRONIC CONSTIPATION

Also Published As

Publication number Publication date
AU2011218009A1 (en) 2012-09-13
CA2790213A1 (en) 2011-08-25
US20230340025A1 (en) 2023-10-26
US20140073571A9 (en) 2014-03-13
US20200283479A1 (en) 2020-09-10
EP2536742A2 (en) 2012-12-26
AU2011218009B2 (en) 2016-11-03
UA108636C2 (xx) 2015-05-25
EP2536742B1 (en) 2017-07-19
TR201711271T4 (tr) 2019-02-21
DK2536742T3 (en) 2017-09-04
WO2011103311A3 (en) 2011-12-29
US20220227812A1 (en) 2022-07-21
CN102869677A (zh) 2013-01-09
AU2017200588A1 (en) 2017-02-23
US8933030B2 (en) 2015-01-13
CN102869677B (zh) 2015-07-08
MX2012009597A (es) 2012-09-28
PL2536742T3 (pl) 2017-11-30
WO2011103311A2 (en) 2011-08-25
ES2638589T3 (es) 2017-10-23
US20150094265A1 (en) 2015-04-02
MX340234B (es) 2016-07-01
US20210388026A1 (en) 2021-12-16
US20130190238A1 (en) 2013-07-25
AU2019202052A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
EA201290799A1 (ru) Лечение желудочно-кишечных расстройств
MX2014001798A (es) Tratamientos para trastornos gastrointestinales.
WO2006086653A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
SG153824A1 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007101158A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007022531A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
LTC1594517I2 (lt) Kompozicijos, skirtos virškinamojo trakto sutrikimų gydymui
WO2008002971A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2005016244A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
JP2011152140A5 (ru)
WO2005074575A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2007062168A3 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2006102069A3 (en) Methods and compositions for the treatment of hypertension and gastrointestinal disorders
CY1113569T1 (el) Μεθοδοι και συνθεσεις για την αγωγη γαστρεντερικων διαταραχων